In speech, Lilly CEO calls for drug monitoring

In a speech at the Cleveland Clinic, Eli Lilly chairman and CEO Sidney Taurel (photo) called for greater use of health IT in order to monitor the effects of prescription drugs. Not only would such a system provide much-needed post-marketing pharmacovigilance, it would also help the industry study drug effectiveness and identify other indications for drugs. A comprehensive, interoperable health IT could collect detailed data on a daily basis, thus helping doctors, regulators, and drug manufacturers notice trends more quickly. The result would be a more accurate picture of a drug's safety and efficacy than exists today.

"The use of prescription medicines always will be a matter of balancing benefits and risks," Taurel said. "Fortunately, systems are now within our grasp to more quickly identify both the true benefits and the full extent of risks associated with medicines in widespread use."

- check out the release on Taurel's speech

ALSO: The FDA has posted a letter on its website warning Lily to stop making "false and misleading" claims about its antidepressant Cymbalta. Report

Related Articles:
Lilly developing biotech drugs the old-fashioned way. Report
Pharma, FDA to study adverse events. Report
Bickering may stall trial database. Report

Suggested Articles

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.